Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.64 |
| ▸ | ESR1 | P03372 | 4/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.64 |
| ▸ | NQO2 | P16083 | 4/20 | 0.64 |
| ▸ | AHR | P35869 | 3/20 | 0.64 |
| ▸ | TTR | P02766 | 3/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.64 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.64 |
| ▸ | BCR | P11274 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.64 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.64 |
| ▸ | TUBB | P07437 | 2/20 | 0.64 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.64 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.64 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.64 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542593 | 1.00 | CYP1A1 (0.64) | CYP1A1CYP1B1ESR1PTGS2NQO2 | |
| SCHEMBL10276760 | 1.00 | CYP1A1 (0.64) | CYP1A1CYP1B1ESR1PTGS2NQO2 | |
| SCHEMBL3544223 | 0.98 | CYP1A1 (0.67) | CYP1A1CYP1B1ESR1PTGS2NQO2 | |
| SCHEMBL3544226 | 0.98 | CYP1A1 (0.67) | CYP1A1CYP1B1ESR1PTGS2NQO2 | |
| SCHEMBL1975475 | 0.94 | CYP1A1 (0.64) | CYP1A1CYP1B1ESR1PTGS2NQO2 | |
| SCHEMBL1975478 | 0.94 | CYP1A1 (0.64) | CYP1A1CYP1B1ESR1PTGS2NQO2 | |
| SCHEMBL3551213 | 0.94 | CYP1A1 (0.64) | CYP1A1CYP1B1ESR1PTGS2NQO2 | |
| SCHEMBL21356550 | 0.92 | ESR1 (0.50) | CYP1A1CYP1B1ESR1PTGS2NQO2 | |
| SCHEMBL7193989 | 0.87 | CYP1A1 (0.46) | CYP1A1CYP1B1ESR1PTGS2NQO2 | |
| SCHEMBL21356573 | 0.84 | PTGS2 (0.53) | CYP1A1CYP1B1ESR1PTGS2NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705188-B2 | Structural modification of resveratrol: sodium resverastatin phosphate | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University (US) | 2010-04-27 | — | — | US | claimed |
| US-8426369-B2 | Prevention and treatment of colon cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-07-12 | — | — | US | disclosed |
| US-7705188-B2 | Structural modification of resveratrol: sodium resverastatin phosphate | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University (US) | 2010-04-27 | — | — | US | disclosed |
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | NATIONAL INSTITUTES OF HEALTH | 2005-10-27 | — | — | US | disclosed |
| WO-2003086414-A1 | STRUCTURAL MODIFICATION OF RESVERATROL: SODIUM RESVERASTATIN PHOSPHATE | ARIZONA BOARD OF REGENTS (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | PI4KB, HDAC4, PIK3CA | CYP1A1 3525/4885CYP1B1 2430/4885ESR1 1221/4885 |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | APC, SI, NFKBIA | CYP1A1 1123/4885CYP1B1 1133/4885ESR1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.